Hearing Loss Clinical Trial Pipeline Gains Momentum: 30+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s, “Hearing Loss Pipeline Insight 2026” report provides comprehensive insights about 30+ companies and 35+ pipeline drugs in Hearing Loss pipeline landscape. It covers the Hearing Loss pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hearing Loss therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight’s comprehensive Hearing Loss Pipeline Report @ Hearing Loss Pipeline Outlook Report

Key Takeaways from the Hearing Loss Pipeline Report

• On May 22, 2026- Sound Pharmaceuticals Incorporatedinitiated a clinical trial is to learn about the effects of drug SPI-1005 in adults receiving a cochlear implant with a long electrode array (FLEX26 or greater) from MED-EL Cochlear Implant Systems into one ear.
• On May 05, 2026- Regeneron Pharmaceuticals announced a phase 1/2 study of an investigational new drug called DB-OTO. DB-OTO is a gene therapy that is being developed to treat children who have hearing loss due to changes in the otoferlin gene.
• DelveInsight’s Hearing Loss pipeline report depicts a robust space with 30+ active players working to develop 35+ pipeline therapies for Hearing Loss treatment.
• The leading Hearing Loss Companies such as Sensorion, AudioCure Pharma GmbH, Acousia Therapeutics, Neuracle Science, Regeneron Pharmaceuticals, Sound Pharmaceuticals, PAEAN Biotechnology and others.
• Promising Hearing Loss Therapies such as AM-111, FX-322, AUT00063, FX-322 (One Dose), AC102 Gel, Prednisolone, OTO-413, and others.

Access DelveInsight’s in-depth Hearing Loss Pipeline Analysis for a closer look at promising breakthroughs @ Hearing Loss Clinical Trials and Studies

Hearing Loss Overview

Hearing loss refers to a partial or total inability to hear, which can be present at birth or develop later in life. It can affect one or both ears and is categorized into three main types: conductive hearing loss, caused by issues in the outer or middle ear; sensorineural hearing loss, stemming from damage to the inner ear or auditory nerve; and mixed hearing loss, which involves both conductive and sensorineural components. Hearing loss can manifest through various signs and symptoms, often developing gradually and becoming noticeable over time. Common indicators include difficulty hearing conversations, especially in noisy environments, frequently asking others to repeat themselves, and needing to increase the volume on devices like televisions or radios compared to others. Individuals may also experience muffled sounds, misunderstandings during conversations, and fatigue from concentrating on listening.

Hearing Loss Emerging Drugs Profile

• SENS-401: Sensorion

SENS-401 (Arazasetron), Sensorion’s clinical stage drug candidate, is an orally available small molecule that aims to protect and preserve inner ear tissue from damage responsible of progressive or sequelae hearing impairment. Sensorion currently develops SENS-401 in a Phase 2 clinical trial for the prevention of Cisplatin-Induced Ototoxicity and has completed a Phase 2a study to prevent residual hearing loss in patients scheduled for cochlear implantation. SENS-401 has been granted Orphan Drug Designation by the EMA in Europe for the treatment of sudden sensorineural hearing loss, and by the FDA in the US for the prevention of platinum-induced ototoxicity in pediatric population. Currently, the drug is in Phase II/III stage of its clinical trial for the treatment of Hearing Loss.

• ACOU-085: Acousia Therapeutics

ACOU085 is a first-in-class, small-molecule, etiology-agnostic otoprotective drug candidate delivered using standard, transtympanic administration of a proprietary, slow-release gel formulation. Ototoxic hearing loss is a typical, severe, and permanent side effect of cisplatin treatment and is a consequence of irreversible damage to the sensory cells in the inner ear, the so-called outer hair cells (OHCs). ACOU085 modulates a biologically validated target, the KCNQ4-encoded Kv7.4 potassium channel of the OHCs, and has demonstrated significant potential to reduce cisplatin-induced hearing loss and preserve outer hair cells from ototoxicity in preclinical models. Currently, the drug is in Phase II stage of its clinical trial for the treatment of hearing loss.

• NS101: Neuracle Science

NS101 is a monoclonal antibody developed by Neuracle Science Co., Ltd., targeting TAFA5, a protein associated with neurodegenerative diseases such as sensorineural hearing loss and Alzheimer's disease. By modulating TAFA5 activity, NS101 aims to restore neural function and mitigate disease progression. Currently, NS101 is undergoing Phase I/II clinical trials to evaluate its safety, tolerability, pharmacokinetics, and preliminary efficacy in both healthy volunteers and patients with sudden sensorineural hearing loss.

Get a detailed analysis of the latest innovations in the Hearing Loss pipeline @ Hearing Loss Unmet Needs

Hearing Loss Companies

Sensorion, AudioCure Pharma GmbH, Acousia Therapeutics, Neuracle Science, Regeneron Pharmaceuticals, Sound Pharmaceuticals, PAEAN Biotechnology and others.

Hearing Loss pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Hearing Loss Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Download DelveInsight’s latest report to gain strategic insights into upcoming therapies and key developments @ Hearing Loss Market Drivers and Barriers, and Future Perspectives

Scope of the Hearing Loss Pipeline Report

• Coverage- Global
• Hearing Loss Companies- Acousia Therapeutics, Decibel Therapeutics, Otonomy Inc., Sensorion, Autifony Therapeutics, Auris Medical, Sound Pharmaceuticals, Anida Pharma Inc., Gateway Biotechnology, Myrtelle Inc., Lineage Cell Therapeutics, Inc., Altamira Therapeutics, Hoba Therapeutics, Rinri Therapeutics, Autifony Therapeutics, Otologic Pharmaceutics, Audion Therapeutics, Perha Pharmaceuticals, Applied Genetic Technologies Corporation, Akouos, Inc., Oricula Therapeutics, Spiral Therapeutics, Pipeline Therapeutics, Prime Medicine, Boehringer Ingelheim, Autigen, Heyu (Suzhou) Pharmaceutical Technology Co., Ltd, Astellas Pharma, Mogrify Limited and others.
• Hearing Loss Therapies- AM-111, FX-322, AUT00063, FX-322 (One Dose), AC102 Gel, Prednisolone, OTO-413, andothers.
• Hearing Loss Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Hearing Loss Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Find out in DelveInsight’s exclusive Hearing Loss Pipeline Report—access it now! @ Hearing Loss Emerging Drugs and Major Companies

Table of Content

1. Introduction
2. Executive Summary
3. Hearing Loss: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Hearing Loss– DelveInsight’s Analytical Perspective
7. Mid Stage Products (Phase II/III)
8. SENS-401: Sensorion
9. Drug profiles in the detailed report…..
10. Early Stage Products (Phase I/II)
11. OTO-413: Otonomy Inc.
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. ACOU085: Acousia Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Research programme: Hearing Loss: Autifony Therapeutics
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Hearing Loss- Unmet Needs
21. Hearing Loss- Market Drivers and Barriers
22. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/hearing-loss-pipeline-insight

Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Hearing Loss Clinical Trial Pipeline Gains Momentum: 30+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight